– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – Publication of the Budget Impact Model ...
Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals and ...
NEWTON, Mass.--(BUSINESS WIRE)--Axena Health, Inc. (Axena Health), a women’s health company redefining the standard of care for pelvic health conditions through clinically proven, non-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results